Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met major and all key secondary endpoints; favorable security and tolerability information noticed Single dose of lonvo-z freed most sufferers from each assaults and ongoing remedy for six-month efficacy analysis interval, demonstrating its potential to be the primary and solely one-time HAE therapy Rolling biologics license software…
